Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus

Journal of Virology

Volumn 70, Issue 11, 1996, Pages 7783-7791

  Hancock, Gerald E ^a   Speelman, Dan J ^a   Heers, Kristen ^a   Bortell, Eric ^a   Smith, Jason ^a   Cosco, Cynthia ^a  

^a Lederle Praxis Biologicals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; FORMALDEHYDE; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; INTERLEUKIN 5; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; SAPONIN; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HELPER CELL; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; KILLER CELL; LOEFFLER PNEUMONIA; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SPLEEN CELL; VERO CELL; VIRUS PNEUMONIA;

EID: 0029817240     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.11.7783-7791.1996     Document Type: Article

References (55)

1. Alwan, W. H., W. J. Kozlowska, and P. J. M. Openshaw. 1994. Distinct types of lung disease caused by functional subsets of antiviral T cells. J. Exp. Med. 179:81-89.
2. Alwan, W. H., F. M. Record, and P. J. M. Openshaw. 1993. Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins. J. Immunol. 150:5211-5218.
3. Belshe, R. B., L. P. Van Voris, and M. A. Mufson. 1982. Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J. Inf. Dis. 145:311-319.
4. Brideau, R. J., and M. W. Wathen. 1991. A chimeric glycoprotein of human respiratory syncytial virus termed FG induces T-cell mediated immunity in mice. Vaccine 9:863-864.
5. Chanock, R. M., and R. H. Parrott. 1965. Acute respiratory disease in infancy and childhood: present understanding and prospects for prevention. Pediatrics 36:21-39.
6. Chanock, R. M., R. H. Parrott, M. Connors, P. L. Collins, and B. R. Murphy. 1992. Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. Pediatrics 90: 137-143.
7. Cherrie, A. H., K. Anderson, G. W. Wertz, and P. J. M. Openshaw. 1992. Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. J. Virol. 56:2102-2110.
8. Coffman, R. L., B. W. P. Seymour, S. Hudak, J. Jackson, and D. Rennick. 1989. Antibody to interleukin-5 inhibits helminth-induced cosinophilia in mice. Science 245:308-310.
9. Colocho Zelaya, E. A., C. Orvell, and O. Strannegard. 1994. Eosinophil cationic protein in nasopharyngeal secretions and serum of infants infected with respiratory syncytial virus. Pediatr. Allergy Immunol. 5:100-106.
10. Connors, M., P. L. Collins, C.-Y. Firestone, A. V. Sotnikov, A. Waitze, A. R. Davis, P. P. Hung, R. M. Chanock, and B. R. Murphy. 1992. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 10:475-484.
11. Connors, M., N. A. Giese, A. B. Kulkarni, C.-Y. Firestone, H. C. Morse, and B. R. Murphy. 1994. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J. Virol. 68:5321-5325.
12. + T cells. J. Virol. 66:7444-7451.
13. Curry, R. C., P. A. Kiener, and G. L. Spitalny. 1987. A sensitive immunochemical assay for biologically active Mu IFN-γ. J. Immunol. Methods 104: 137-142.
14. Dubucquoi, S., P. Desreumaux, A. Janin, O. Klein, M. Goldman, J. Tavernier, M. Capron, and A. Capron. 1994. Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J. Exp. Med. 179:703-709.
15. Fernie, B. F., E. C. Ford, and J. L. Gerin. 1981. The development of BALB/c cells persistently infected with respiratory syncytial virus: presence of ribonucleoprotein on the cell surface (41129). Proc. Soc. Exp. Biol. Med. 167: 83-86.
16. Garofalo, R., J. L. L. Kimpen, R. C. Welliver, and P. L. Ogra. 1992. Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J. Pediatr. 120:28-32.
17. Graham, B. S., G. S. Henderson, Y.-W. Tang, X. Lu, K. M. Neuzil, and D. G. Colley. 1993. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J. Immunol. 151:2032-2040.
18. Hall, C. B., E. E. Walsh, C. E. Long, and K. C. Schnabel. 1991. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163:693-698.
19. Hancock, G. E., D. J. Hahn, D. J. Speelman, S. W. Hildreth, S. Pillai, and K. McQueen. 1994. The pulmonary immune response of BALB/c mice vaccinated with the fusion protein of respiratory syncytial virus. Vaccine 12:267-274.
20. Hancock, G. E., D. J. Speelman, P. J. Frenchick, M. M. Mineo-Kuhn, R. B. Baggs, and D. J. Hahn. 1995. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in BALB/c mice that are similar to those generated by experimental infection. Vaccine 13:391-400.
21. Issacs, D., N. E. MacDonald, C. R. M. Bangham, A. J. McMichael, P. G. Higgins, and D. A. J. Tyrrell. 1991. The specific cytotoxic T-cell response of adult volunteers to infection with respiratory syncytial virus. Immunol. Infect. Dis. 1:5-12.
22. Johnson, P. R., M. K. Spriggs, R. A. Olmsted, and P. L. Collins. 1987. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc. Natl. Acad. Sci. USA 84:5625-5629.
23. Kakuk, T. J., K. Soike, R. J. Brideau, R. M. Zaya, S. L. Cole, J.-Y. Zhang, E. D. Roberts, P. A. Wells, and M. W. Wathen. 1993. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine hut not a recombinant FG subunit vaccine. J. Infect. Dis. 167:553-561.
24. Kapikian, A. Z., R. H. Mitchell, R. M. Chanock, R. A. Shevdoff, and C. E. Stewart. 1968. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89:405-413.
25. Kensil, C. R., U. Patel, M. Lennick, and D. Marciani. 1991. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 146:431-437.
26. Kim, H. W., J. O. Arrobio, C. D. Brandt, P. Wright, D. Hodes, R. M. Chanock, and R. H. Parrott. 1973. Safety and antigenicity of temperature-sensitive (TS) mutant respiratory syncytial virus (RSV) in infants and children. Pediatrics 52:56-63.
27. Kim, H. W., J. O. Arrobio, C. Pyles, C. D. Brandt, E. Camargo, R. M. Chanock, and R. H. Parrott. 1971. Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus. Pediatrics 48:745-755.
28. Kim, H. W., J. G. Canchola, C. D. Brandt, G. Pyles, R. M. Chanock, K. Jensen, and R. H. Parrott. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
29. Kim, H. W., S. L. Leikin, J. Arrobio, C. D. Brandt, R. M. Chanock, and R. H. Parrott. 1976. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or infection. Pediatr. Res. 10:75-78.
30. Kimpen, J. L. L., R. Garofalo, R. C. Welliver, and P. L. Ogra. 1992. Activation of human eosinophils in vitro by respiratory syncytial virus. Pediatr. Res. 32:160-164.
31. Lammas, D. A., L. A. Mitchell, and D. Wakelin. 1989. Genetic control of eosinophilia. Analysis of production and response to cosinophil-differentiating factor in strains of mice infected with Trichinella spiralis. Clin. Exp. Immunol. 77:137.
32. Ma, J., P. A. Bulger, D.vR. Davis, B. Perilli-Palmer, D. A. Bedore, C. R. Kensil, E. M. Young. C.-H. Hung, J. R. Seals, C. S. Pavia, and R. T. Coughlin. 1994. Impact of the saponin adjuvant OS-21 and aluminum hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi. Vaccine 12:925-932.
33. Mosmann, T. R., J. H. Schumacher, N. F. Street, R. Budd, A. O. Garra, T. A. T. Fong, M. W. Bond, K. M. W. Moore, A. Sher, and D. F. Fiorentino. 1991. Diversity of cytokine synthesis and function of mouse CD4+ T cells. Immunol. Rev. 123:209-229.
34. Muelenaer, P. M., F. W. Henderson, V. G. Hemming, E. E. Walsh, L. J. Anderson, G. A. Prince, and B. R. Murphy. 1991. Group-specific serum antibody responses in children with primary and recurrent respiratory syncytial virus infections. J. Infect. Dis. 164:15-21.
35. Murphy, B. R., D. W. Alling, M. H. Snyder, E. E. Walsh, G. A. Prince, R. M. Chanock, V. C. Hemming, W. J. Rodriguez, H. W. Kim, B. S. Graham, and P. F. Wright. 1986. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J. Clin. Microbiol. 24:894-898.
36. Murphy, B. R., S. L. Hall, A. B. Kulkarni, J. E. Crowe, P. L. Collins, M. Connors, R. A. Karron, and R. M. Chanock. 1994. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 32:13-36.
37. Murphy, B. R., G. A. Prince, E. E. Walsh, H. W. Kim, R. H. Parrolt, V. G. Hemming, W. J. Rodriguez, and R. M. Chanock. 1986. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J. Clin. Microhiol. 24:197-202.
38. + cytotoxic T lymphocyte responses. J. Immunol. 148:2357-2362.
39. + T cells into subpopulations with distinct profiles. J. Immunol. 155:2928-2937.
40. Piedra, P. A., P. R. Wyde, W. L. Castleman, M. A. Ambrose, A. M. Jewell, D. J. Speelman, and S. W. Hildreth. 1993. Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon. Vaccine 11:1415-1423.
41. + T cells secreting Th1 or Th2 cytokines. Immunity. 2:271-279.
42. + T-cell clones. Science 254:279.
43. Satake, M., J. E. Coligan, N. Elango, E. Norrby, and S. Venkatesan. 1985. Respiratory syncytial virus envelope glycoprotein (G) has a novel structure. Nucleic Acids Res. 13:7795-7812.
44. Spitalny, G. L., and E. A. Havell. 1984. Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities. J. Exp. Med. 159:1560-1565.
45. Stanley, C. J., A. Johannsson, and C. H. Self. 1985. Enzyme amplification can enhance both the speed and the sensitivity of immunoassays. J. Immunol. Methods 83:898-95.
46. Storch, G. A., L. J. Anderson, C. S. Park, C. Tsou, and D. E. Dohner. 1991. Antigenic and genomic diversity within group A respiratory syncytial virus. J. Infect. Dis. 163:858-861.
47. Stott, E. J., and G. Taylor. 1985. Respiratory syncytial virus, brief review. Arch. Virol. 84:1-52.
48. Taylor, G., E. J. Stott, E. M. Bew, B. F. Fernie, P. J. Cote, A. P. Collins, M. Hughes, and J. Jebbet. 1984. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 52:137-142.
49. Toms, G. L. 1991. Vaccination against respiratory syncytial virus: problems and progress. FEMS Microbiol. Immunol. 76:243-256.
50. Trinchieri, G. 1994. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 12:4008-4027.
51. Tristram, D. A., R. C. Welliver, C. K. Mohar, D. A. Hogerman, S. W. Hildreth, and P. Paradiso. 1993. Immunogenicity and safety of a respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J. Infect. Dis. 167:191-195.
52. Trudel, M., F. Nadon, C. Seguin, and H. Binz. 1991. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from G glycoprotein. Virology 185:749-757.
53. Walsh, E. E., J. J. Schlesinger, and M. W. Brandriss. 1984. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect. Immun. 43:756-758.
54. Walsh, E. E., J. J. Schlesinger, and M. W. Brandriss. 1984. Purification and characterization of GP90. one of the envelope glycoproteins of respiratory syncytial virus. J. Gen. Virol. 65:761-767.
55. Warren, H. S., B. F. Kinnear, J. H. Phillips, and L. L. Lanier. 1995. Production of IL-5 by human NK cells and regulation of IL-5 secretion by IL-4, IL-10, and IL-12. J. Immunol. 154:5144-5152.